Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 27;8(10):1556. doi: 10.3390/jcm8101556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Expression of programmed death receptor 1 (PD-1) in PZA treated granulomas. PD-1 T cells were measured with an anti-PD1 primary monoclonal antibody conjugated with HRP. A secondary anti-mouse PE-Cy5 antibody was added after blocking with 0.1% Triton X for 1 h. The nuclei of cells were stained with DAPI. The mean fluorescence of PD-1 was corrected with the mean DAPI fluorescence. (A) PD-1 mean fluorescence from non-vaccinated subjects with L-GSH treatment along with PD-1 fluorescent images; (B) PD-1 mean fluorescence from BCG vaccinated subjects with L-GSH treatment along with PD-1 fluorescent images; (C) PD-1 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) PD-1 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH treatment; (F) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it. (G) PD-1 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subjects; (H) PD-1 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it.

Expression of programmed death receptor 1 (PD-1) in PZA treated granulomas. PD-1 T cells were measured with an anti-PD1 primary monoclonal antibody conjugated with HRP. A secondary anti-mouse PE-Cy5 antibody was added after blocking with 0.1% Triton X for 1 h. The nuclei of cells were stained with DAPI. The mean fluorescence of PD-1 was corrected with the mean DAPI fluorescence. (A) PD-1 mean fluorescence from non-vaccinated subjects with L-GSH treatment along with PD-1 fluorescent images; (B) PD-1 mean fluorescence from BCG vaccinated subjects with L-GSH treatment along with PD-1 fluorescent images; (C) PD-1 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) PD-1 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH treatment; (F) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it. (G) PD-1 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subjects; (H) PD-1 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it.